Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Faktu is a topical combination medication indicated for the treatment of various anorectal disorders, most notably hemorrhoids, anal fissures, and proctitis. It consists of two active components: policresulen and cinchocaine hydrochloride. Policresulen is a polymolecular organic acid that acts as a local hemostatic and astringent; it selectively coagulates necrotic or pathologically altered tissue while leaving healthy squamous epithelium unaffected, thereby promoting healing and preventing infection. Cinchocaine hydrochloride (also known as dibucaine) is a potent amide-type local anesthetic that provides symptomatic relief from pain, burning, and pruritus by inhibiting the initiation and conduction of nerve impulses through the blockade of voltage-gated sodium channels. The product was originally developed by Altana (later Nycomed and Takeda) and is currently part of the pharma& Group portfolio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on policresulen + cinchocaine.